OUR STORY

Tessa Therapeutics is founded on over three decades of research and development by our Scientific Co-Founder, Dr. Malcolm K Brenner, and his team at Baylor College of Medicine. Leveraging the potential of the body’s natural anti-viral immune response as a therapy for cancer treatment, Tessa Therapeutics is emerging with a new approach to cell therapy for hematologic malignancies and solid tumors.

Learn More

OUR SCIENCE

Tessa Therapeutics is building a portfolio of next-generation autologous and allogeneic cell therapies by combining T cells with other immuno-oncology approaches. Our cell therapy platform technology is characterized by CD30-Chimeric Antigen Receptors and Virus-Specific T Cells. Tessa Therapeutics is also developing a novel, allogeneic platform technology by combining both technologies to create off-the-shelf cell therapies against a variety of hematologic malignancies and solid tumors.

Learn More

OUR PIPELINE

Our portfolio of autologous and allogeneic cell therapies are built on platforms that combine T cells with other immuno-oncology approaches. Our lead candidate comprises autologous CD30 CAR-T cell therapy targeting classical Hodgkin lymphoma (cHL) and CD30+ non-Hodgkin lymphomas.

Learn More

OUR OPERATIONS

Our global manufacturing and supply chain capabilities will be substantially enhanced by a new commercial-scale GMP facility which is slated to operate in 2021. This will enable Tessa Therapeutics to rapidly and reliably bring safe and effective treatment options to patients.

Learn More
null

Our Story

null

Our Science

null

Our Pipeline

null

Our Operations

News & Events

Tessa at a Glance

200+ Employees Globally
Advanced Pipeline
Global Operational Reach
3 Research & Development Labs
6 Strategic Partnerships
Upcoming cGMP Manufacturing Facility
Global Scientific Advisory Board & Key Opinion Leader Network
3 Satellite Labs